Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees
Louisville, Colo. and Chicago, Ill. – January 30, 2020 – GID BIO announced the acceptance by the American Journal of Sports Medicine to publish results next month of an FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis. [Read more…]